SCA
MDGL icon

SAC Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

SAC Capital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-57,309
Closed -$12.7M – 1890
2013
Q3 		$12.7M Sell
57,309
-777
-1% -$165K 0.07% 316
2013
Q2 		$10.1M Buy
+58,086
New +$15.1M 0.06% 363

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's MDGL Position: Q4 2013 in Review

SAC Capital Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2013, closing a stake of 57,309 shares — an estimated $12.7M sold.

SAC Capital Advisors first reported a position in MDGL in Q2 2013 and held it in 2 quarters. The position peaked at $12.7M in Q3 2013. 77 funds tracked by Wall St. Rank hold MDGL as of Q4 2013.

  • SAC Capital Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • SAC Capital Advisors sold 57,309 Madrigal Pharmaceuticals shares in Q4 2013, an estimated $12.7M.
  • SAC Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • SAC Capital Advisors's Madrigal Pharmaceuticals position peaked at $12.7M in Q3 2013.
  • 77 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2013.

Based on SAC Capital Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.